5-iodo-3,7-dimethyl-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one | 1410974-79-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 5-iodo-3,7-dimethyl-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one
• 英文别名: 5-iodo-3,7-dimethylpyrrolo[2,3-d]pyrimidin-4-one
• CAS: 1410974-79-6
• 化学式: C₈H₈IN₃O
• 分子量: 289.076
• InChiKey: ZQAQXZKVXWKKDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  37.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-羟基吡咯并[2,3-d]嘧啶 在 N-碘代丁二酰亚胺 、 N,O-双三甲硅基乙酰胺 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 5-iodo-3,7-dimethyl-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one
  参考文献：
  名称：

  PYRIMIDO-DIAZEPINONE COMPOUND

  摘要：

  公开号：

  EP2708540B1

文献信息

• PYRIMIDODIAZEPINONE COMPOUND
  申请人：Otsubo Nobumasa

  公开号：US20140171422A1

  公开（公告）日：2014-06-19

  Provided are a compound represented by general formula (I), or the pharmaceutically acceptable salt thereof, (wherein R a represents a hydrogen atom or the like, R 1 and R 2 may be the same or different, and each represents a hydrogen atom, optionally substituted lower alkyl or cycloalkyl, or R 1 and R 2 are combined together with the adjacent nitrogen atom thereto to form nitrogen-containing heterocyclic group, and Z represents a bicyclic heterocyclic group in which optionally substituted two six-membered rings are fused to each other, or the like) and the like.

  提供一种由通式（I）表示的化合物，或其药学上可接受的盐（其中Rarepresents表示氢原子或类似物，R1和R2可以相同也可以不同，每个表示氢原子，可选地取代的低碳基或环烷基，或者R1和R2与毗邻的氮原子结合形成含氮杂环基，Z表示一个双环杂环基，在其中可选地取代的两个六元环相互融合，或类似物）。
• Azapeptide derivatives
  申请人：Harbeson Scott L.

  公开号：US20090036357A1

  公开（公告）日：2009-02-05

  This invention relates to novel compounds that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir.
• US9453021B2
  申请人：——

  公开号：US9453021B2

  公开（公告）日：2016-09-27